You will receive a full printed programme including abstracts and panels at the conference.
8:00 am – 9:00 am: | Registration | |||
9:00 am – 9:30 am | Opening and Welcome | |||
9:30 am – 10:15 am | Keynote Presentation: | |||
10:15 am – 10:45 am | MORNING TEA | |||
Session Theme | Drug policy differentiation | Policy responses to drug problems | Debating Drugs in Media | New psychoactive substances |
Discussant chair | Vibeke A. Frank | Nicola Singleton | Steven Jonas | Peter Reuter |
A 10:45 am – 12:15 pm | Panel 1: Drug policy differentiation: accommodating diversity and marginality Panelists: Elizabeth Ettorre Emma Wincup Daniel Bear Aileen O’Gorman Aims: Drug use by women, minority ethnic and marginalised groups is differentially stigmatised and problematised. These same social groups experience disproportionate levels of drug-related harms. Despite this, drug policies focus on addressing individual drug-using behaviours, through law enforcement, treatment, and outreach, as if these behaviours were context free and unaffected by structured inequalities. Rarely, in the development of drug policy, is the unequal experience of harms predicated by gender, race and class acknowledged or addressed. Moreover, the implementation of these policies can lead to harms which are disproportionately felt by these social groups. The presentations in this panel will explore the differentiated impact of drug policies and drug-related harms on women, trans men and women, black and minority ethnic groups, and marginalised socio-economic groups and communities. Drawing on case studies from their research, panellists will frame their presentations around the following questions: what is the impact of criminal justice; public health; and recovery approaches to drug policy on these social groups? How can drug policies best address difference, marginality and intersectionality? | Alison Ritter, Caitlin Hughes, Kari Lancaster, Rob Hoppe Drug detection dogs seen through the eyes of the Advocacy Coalition Framework compared to Multiple Streams: the science-policy interface | Lena Eriksson The needle exchange debate in Stockholm City Council and Swedish Parliament during the 21st century | Robert Csák, József Rácz How environmental factors can increase the risks of PWIDs - a case study of Budapest, Hungary
|
Claudia Rafful, Orozco R, Rangel G, Davidson P, Gonzalez-Zúñiga P, Werb D, Beletsky L, Strathdee SA. Increased non-fatal overdose risk associated with involuntary drug treatment in a longitudinal study with people who inject drugs in Tijuana, Mexico | Mauricio Coitiño, Rosario Queirolo, Alejandra Triñanes Same laws, different messages: the framing effect on the press coverage of the regulation of cannabis and alcohol in Uruguay | Rob Ralphs and Paul Gray Caught in the act: The impact of the Psychoactive Substances Act on vulnerable users | ||
Alisa Pedrana, Joseph Doyle, Alex Thompson, Paul Dietze, Mark Stoove, Jacqui Richmond, Judy Gold, Peter Higgs, Margaret Hellard EC!: A partnership to eliminate hepatitis C in Australia | Marie Jauffret-Roustide Drug consumption rooms: issues of social acceptability in French public debate | Maurits Beltgens Examining the impact of the UK blanket ban on psychoactive substances on the UK’s legal high market | ||
| My Lilja Drug discourses in Russian parliamentary debate |
| ||
12:15 pm – 1:15 pm | LUNCH | |||
Session Theme | Harms, trends & pleasures | Comparative analyses of drug policy and drug use | Drug policies and history |
|
Discussant chair | Esben Houborg | Axel Klein | Geoffrey Hunt |
|
B 1:15 pm – 2:45 pm | Mark Monaghan, Ian Hamilton The Risk,benefits and realism: The implications of the abscence of pleasure in public health campaigns and interventions around cannabis | Aysel Sultan Drug policies of Azerbaijan and Germany reflected in narratives of high-risk drug user adolescents | Robin Room Legalising after prohibition: alcohol's lessons for other drugs |
|
Peter Reuter; Bryce Pardo; Jonathan Caulkins Can sentences for drug offenses credibly reflect differences in the harms of drugs? | Anke Stallwitz Community policy at the micro-social level: Utilizing community-mindedness to reduce violence in the Vancouver and the Stockholm drug scene | David McDonald, Alison Ritter Innovations in drug policy interventions over the past decade: an overview and assessment |
| |
Bryce Pardo What relationship does access to cannabis have on the consumption of synthetic cannabinoids? | Luca Giommoni, Peter Reuter, Beau Kilmer The perils of cross national comparisons of drug prevalence: the effect of survey modality | April Henning The escalating of the war on doping in 2016 |
| |
Jasmina Burdzovic Andreas; Anne Line Bretteville-Jensen
Ready, willing, and able: The role of cannabis use opportunities in understanding adolescent cannabis use | Majid Alaee, Mahmoud Jahan Tigh A study on the prevalence of medication/polymedication abuse in Iran | Yun Huang “With a mill-stone about her neck”: China’s participation of the 1924-1925 Geneva Opium Conferences and its impacts | ||
2:45 pm – 3:15 pm | AFTERNOON TEA | |||
Session Theme | Production and distribution of cannabis and methamphetamine | Harm reduction | Methadone treatment | Prison, treatment & drug use
|
Discussant chair | Jonathan Caulkins | Susanne MacGregor | Bagga Bjerge | Emma Wincup |
C 3:15 pm – 5:00 pm
| Steven Davenport Do marijuana stores increase local traffic accidents? Evidence from Oregon
| Andy Guise, Amen Hamida, Maria Luisa Mittal, Claudia Rafful, Peter Davidson, Daniel Werb Harm reduction, choice and pleasure in structural responses to injecting initiation; insights from qualitative research in the Mexico-U.S. border region | Tim Rhodes, James Ndimbii, Emmy Kageha, Frederick Owiti, Steffanie Strathdee, Andy Guise The becoming of methadone treatment in Kenya: A qualitative study of implementation
| Petr Zeman, Michaela Štefunková, Šárka Blatníková, Kateřina Grohmannová, Tomáš Koňák, Ivana Trávníčková Treatment in an unfavourable setting: Specialized departments for drug users in Czech prisons |
Simon Lenton, Vibeke Frank, Monica Barratt, Gary Potter Growing practices and the use of chemical additives among a sample of small scale cannabis growers in three countries | Kati Kataja New practices of harm reduction? Sharing risk experiences of polydrug use on YouTube | Roya Noori. Masoud Lotfizadeh, Babak Moazen, Nazgol Mostafavinasab, Hooman Narenjiha Methadone maintenance treatment entry and retention among Iranian drug user women: A qualitative study in Iran | Karen Duke Producing the ‘problem’ of New Psychoactive Substances (NPS) in English prisons | |
Mafalda Pardal “The difference is in the tomato at the end”: understanding the role and practices of cannabis growers operating within Belgian cannabis social clubs | Truong Tuan Dung A qualitative and quantitative study to critically explore perceptions of harm reduction policy and practice in Vietnam | Thu T.A. Vuong, Nhu T. Nguyen, Nguyen B. Nguyen, Huy L. Pham, Huong Q. Nguyen From free service to co-payment model: Effects of the transition on patient adherence and service quality of the Methadone Maintenance Treatment program in Vietnam | Yifen Lu, Yichun Yu, and Chuen-Jim Sheu Evaluation of the deferred prosecution practice for drug abusers: An analysis with big data in Taiwan | |
Jason Ferris The disruption of Australian domestic methamphetamine production: Analysis of pseudoephedrine-based medication sales data |
| Atul Ambekar, Alok Agrawal, Ashwani Mishra, Ravindra Rao Do drug policies impede the availability of treatment of opioid dependence in India (and more so for non-injecting opioid users)? Analysis of epidemiological data from Punjab, India | Torsten Kolind Prison drug treatment: Increasing overlaps between social service and punishment | |
|
| Zahra Alammehrjerdi, Afsaneh Moradi Drug treatment and harm reduction programs for women in Iran: the first women-specific health policy in Western Asia | Kristy Kruithof, Matthew Davies, Emma Disley, Lucy Strang and Kei Ito Mapping the use of alternatives to coercive sanctions as a response to drug law offences and drug-related crimes across the EU | |
5:30 pm – 7:30 pm | WELCOME RECEPTION | |||
8:30 am – 9:15 am | Registration | |||
9:15 am – 10:00 am | Keynote Presentation: | |||
10:00 am – 10:30 am | MORNING TEA | |||
Session Theme | Cryptomarkets | Performance and image enhancing drugs | Alternative regulatory models for cannabis | Developing drug supply indicators |
Discussant chair | Monica Barratt & Peter Reuter | Katinka van de Ven | Simon Lenton | Caitlin Hughes |
D 10:30 am – 12:00 pm | Panel 7: Cryptomarkets – recent empirical developments and theoretical perspectives Panelists:
Aims: Cryptomarket research has matured in the last few years. A central group of researchers, many of whom comprise this panel, have been part of establishing methods and consolidating formative research (see special issue of IJDP, volume 35, 2016). This panel presents new cryptomarket research considering long-term measurements, the meanings and uses of cryptocurrencies, the relevance for organized crime and the long standing relevant question of initiation of drug use. The aim is to bring together new research to further our understanding of the overall impact of cryptomarket emergence upon global drug markets and health/social outcomes.
| Panel 8: HED policy panel I: Performance and Panelists: Aims: To explore public health and law enforcement perspectives for regulating the illicit human enhancement drug (HED) market within the EU. A new kind of drug use has emerged with the growing prevalence of HEDs that have the potential to improve human attributes and abilities. People are using enhancement drugs for various lifestyle purposes such as to lose weight, to increase muscle strength and size, to look younger and/or to enhance sporting performance. In particular the use of performance and image enhancing drugs (PIEDs), a subset of HEDs, are growing in popularity in amateur and fitness sports. There is however little robust information on the use and supply of PIEDs which undermines the evidence-base for designing and implementing law enforcement measures, prevention, harm reduction initiatives and treatment. In fact, evidenced prevention for PIED use is near to non-existent and treatment facilities for substance dependency are not equipped to deal with the specific needs of PIED users. HED Panel I will therefore bring together knowledge of PIED use, problems and markets with a specific focus on the EU, whilst seeking to contribute to practice and policy. | Panel 5: Alternative regulatory models for cannabis in four countries Panelists: Jonathan Caulkins Beau Kilmer Tom Decorte Chris Wilkins John Clare Aims: There is growing popular support for the legalisation of cannabis in a number of countries around the world but only limited awareness of regulatory options other than the familiar and problematic commercial markets for alcohol and tobacco. There is a pressing need to provide greater detail and context to alternative non-commercial regulatory regimes for cannabis to inform public debate and political advocacy. This panel will present different regulatory regimes for cannabis from a number of countries. Each regulatory model reflects the specific legal, institutional and social environments of cannabis use in a country. | Panel 3: Developing drug supply indicators to improve policy monitoring, analysis and practice Panelists: Aims: The panel aims to highlight the challenges associated with using supply-side indicators for policy monitoring and analysis in a range of countries and regions and discuss potential ways of improving existing sources, expanding their use and identifying new indicators and data to provide a more complete and up-to-date picture of illicit drug production and markets and of their impacts. By describing some methodological development work currently underway it aims to stimulate the identification of opportunities for enhancing data collection and policy analysis in this area at both national and regional levels. |
12:00 pm – 1:00 pm | LUNCH | |||
1:00 pm – 1:30 pm | POSTER SESSION IN ROOM (tba) | |||
Session Theme | Darknet and cryptomarkets | Cognitive enhancement drugs | Selling drugs | Drug monitoring and policy indexes |
Discussant chair | Peter Reuter & Monica Barratt | Jeanett Bjønness | Kim Møller | Claudia Costa-Storti |
E 1:30 pm – 3:00 pm | Kristy Kruithof, Judith Aldridge, David Décary-Hétu, Megan Sim, Elma Dujso, Stijn Hoorens Drug trade via cryptomarkets; trends, wholesale versus retail and shipping routes
| Panel 9: HED policy panel II: Cognitive enhancement drugs Panelists: Aims: | Cecep Mustafa ”She/he strives for social justice that will be beneficial to the offender, although it will abandon legal certainty somewhat”: The perceptions of Indonesian judges in sentencing of minor drug offenders | Peter Meylakhs, Eric Sevigny Development of a global policy index measuring national commitments to HIV prevention and treatment among people who inject drugs |
Larissa J. Maier, Monica Barratt, Jason Ferris, Adam Winstock
Do zero tolerance drug policies promote NPS and darknet market use?
| Bernd Werse, Dirk Egger “I don’t do this because I want to get rich” – a comparative analysis of profit oriented drug-dealers in Germany |
Vivienne Moxham-Hall, Caitlin Hughes, Alison Ritter The development and application of an Australian cannabis law index | ||
Angus Bancroft, Kim Masson ‘Nice people doing shady things’: The morality of exchange in darknet cryptomarkets | Judith Aldridge, Lisa Williams, Can profitable drug selling activity be understood as normalized? Drug cryptomarket sellers as drug reform activists | Angelica Meinhofer Prescription drug monitoring programs: the role of asymmetric information on drug availability and abuse | ||
|
|
| ||
3:00 pm – 3:30 pm | AFTERNOON TEA | |||
3:30 pm – 4:15 pm | Keynote Presentation: | |||
Session Theme | Different policy, different consequences | Treatment: complexity and comparison | Mapping drug markets in different ways | Costs of drugs |
Discussant chair | David McDonald | Marie Jauffret-Roustide | Alison Ritter | Beau Kilmer |
F 4:20 pm – 5:30 pm | Stephen Rolles, Fiona Measham, Ole Rogeberg Using multi criteria decision analysis (MCDA) to assess different policy responses to non-medical heroin use | Bagga Bjerge, Jeppe Oute, Louise Christensen Complex cases – complex policies | Julian Broseus, Natacha Gentile, Simon Baechler, Marie Morelato, Pierre Esseiva Studying illicit drug markets through the analysis of its central component: how to provide intelligence by profiling law enforcement seizures | Laura Atuesta Towards an evaluable drug policy; Analysis of six focus groups in Mexico |
Daniel Mauricio Rico Alternative development and drugs supply reduction: who gets the benefits?
| Lynda Berends Policy reform regarding the ‘problem’ of centralized assessment in Victoria’s drug treatment sector | Daan van der Gouwe, Tibor Brunt, Magriet can Laar, Peggey van der Pol Purity, adulteration and price of drugs bought online versus offline in the Netherlands | Anne Line Bretteville-Jensen, Claudia Costa Storti, C. Mikulic, S. Trigueiros, F. Papamalis, P. Piscociu, Kattau Public expenditure on supply reduction policies | |
Maria Luisa Mittal, Claudia Rafful, Devesh Vashishtha, Patricia Gonzales-Zuniga, Peter Davidson, Dan Werb, Andy Guise Drug policy implications of pathways to initiation of injection drug use facilitated by people who inject drugs in Tijuana, Mexico | SeyedehNazgol Mostafavinasab, Roya Noori, Omid Massah, Babak Moazen, Ali Farhoudian, Reza Daneshmand, Sepideh Aryanfard Women-only therapeutic community program and treatment needs in Iran: the first study from the most populated Persian Gulf country | Jonathan Caulkins, Yilun Bao, Imane Fahli, Yutian Guo, Krista Kinnard, Mary Najewicz, Lauren Renaud Big data on a big new market: Insights from suppliers and customers in Washington State’s legal cannabis market | Cláudia Costa Storti, Charlotte Davies Estimating costs of drug treatment – main challenges and concerns | |
Frank Renato Casas Sulca Scenarios and social actors as key determinants of drug policy in Peru: two comparative cases on coca leaf control |
| Kim Moeller, Sveinung Sandberg Putting a price on trust: a qualitative study of mid- and upper-level drug dealers´pricing decisions |
| |
5:30 pm – 6:30 pm | ISSDP Annual General Meeting - Room A | |||
7:00 pm – 9:30 pm | CONFERENCE DINNER at CANblau | |||
8:30 am – 9:00 am | Registration | |||
9:00 am – 9:45 am | Keynote Presentation: | |||
Session Theme | Development and drug policy | Researchers and drug use | Methodology and drug policy research. | Research funding sources and conflicts of interest |
Discussant chair | Alejandro Madrazo Lajous | Monica Barratt | Tom Decorte | Alison Ritter |
G 9:50 am – 11:00 am | Panel 10: New perspectives on the intersection between development and drug policy Panelists: Aims: | Workshop: Are we ready to come out? Discretion, disclosure, identity and the drug researcher’s drug use. Monica Barratt with Judith Aldridge, Gary Potter and Anna Ross
| Katrine Syppli Kohl Risk, knowledge and willful ignorance: Narratives of being knowledgeable in interviews with high-risk drug users | Panel 4: Research funding sources and conflicts of interest: understanding diverse policy positions Panelists: Aims: |
Rebecca Askew From apathy to activism: understanding drug takers perspectives on the law and policy | ||||
Peter Davidson, Rebecca Fielding-Miller, Ricky Bluthenthal. Ethical collaborations between researchers and community organisations serving people who use drugs | ||||
| ||||
11:00 am – 11:20 am | MORNING TEA | |||
Session Theme | The Uruguyan cannabis model | Drug trafficking | Drug user perspectives | Policing drugs in festival, club settings and on the streets |
Discussant chair | Pablo Galain Palermo | Gary Potter | Torsten Kolind | Daniel Bear |
H 11:20 am – 12:50 pm | Panel 2: The Uruguyan cannabis model: update and open issues Panelists: On 10th of December 2013 the Uruguayan parliament passed law 19172 establishing a normative framework which allows control of the cannabis market. The law establishes a new approach to the distribution, consumption and commercialization of cannabis. On the one hand, it intends to contribute to the reduction of the risks and potential damages incurred by those persons who use cannabis for medicinal or recreational purposes (public health), and on the other hand as a measure to improve public safety and coexistence. The model proposes to implement a regulated distribution of cannabis in which the state will have a monopoly of the substance’s distribution. The regulation of cannabis in Uruguay provides legal access through three mechanisms: self-cultivation, cannabis clubs and some pharmacies. So far, the government has not yet implemented access through pharmacies, the channel of largest coverage. Despite this, many things have changed in the country as a result of the new legislation. What are the preliminary results and lessons that can be learned from this period? Data from administrative registers, governmental decrees, focus groups, interviews with main players (growers, members of cannabis clubs and users) and from the major newspapers of Uruguay (2013-2016), as well as a qualitative analysis, will be presented. | Sheryl McCurdy Pawns in Makran: Tanzanians, debt bondage, and drug trafficking strategies | Samhita Bhushan, Atul Ambekar, Abhay Jain
Attitudes and perceptions of retailers and consumers of legal cannabis (bhang) in India | Simon Lenton, Monica Barratt, Jodie Grigg Drug detection dogs at Australian outdoor music festivals: Deterrent, detection and iatrogenic effects |
Allan Gillies The Evolution of State-Narco Networks in Post-Transition Bolivia (1982-1993): Governance, political order and processes of transistion | Paul Gray, Rob Ralphs, Anna Norton. ‘Green heroin’: Synthetic cannabinoid use amongst the homeless in the north of England | Caitlin Hughes, Vivienne Moxham-Hall, Alison Ritter, Rob MacCoun, Don Weatherburn Going out in Sydney: a three month prospective study of the impacts of street-level policing on illicit drug use at outdoor music festivals and licensed entertainment precincts | ||
| Charlotte de Kock, Bert Hauspie, Ilse Derluyn, Tom Decorte, Wouter Vander plasschen, Julie Schamp. A qualitative exploration of perceived discrimination, ethnic identity and social network and their relation to substance use in people with a Turkish and Eastern-European migration background in Ghent, Belgium | Thomas Friis Søgaard, Esben Houborg
Voices of the banished: young people’s experiences of and resistance to nightlife zonal banning orders
| ||
| M. Morales, ML. Mittal, T. Rocha, C. Rafful, E. Clairgue, J. Arredondo, J. Cepeda, SA. Strathdee, L. Beletsky Translating drug policy reform: A qualitative study of policy officer perspective in implementing the Narcomeudeo law reforms in Tijuana, Mexico | |||
12:50 pm – 1:45 pm | LUNCH | |||
Session Theme | Medical cannabis | New developments in harm reduction | New theories in drug policy? | Human rights and UN language |
Discussant chair | Rosalie Liccardo Pacula | Alex Stevens | Thomas Friis Søgaard | Angela Me |
I 1:45 pm – 3:15 pm | Davide Fortin, Marcus Asplund The effects of full legalization on the medical cannabis market in Colorado: Evidence for prescription policy | Panel 6: New developments in harm reduction: panel of the ISSDP/ESC joint working group on European drug policy Panelists: Aims:
| Vanessa Gstrein Ideation, social construction and drug policy: a scoping review | Melissa Bone Human rights, politics and power the case of the UK’s Cannabis Social Club Movement |
Edgar Guerra Prohibition or legalization. The dispute over medical use or recreational consumption of cannabis in Mexico | Anna Ross Developing a critical drug theory: Narrative, knowledge and participation. | Jamie Bridge, Christopher Hallam Dave Bewley Taylor, Marie Nougier, Martin Jelsma Edging forward: How the UN's language on drugs has advanced since 1990 | ||
Sharon Sznitman Do recreational cannabis users, unlicensed and licensed medical cannabis users form distinct groups? | Eric A. Ratliff “A totally different atmosphere”: Co-producing drug contexts through narrative emplacement |
| ||
Axel Klein, Gary Potter The three betrayals of the medical cannabis grower: from multiple victimhood to reconstruction, redemption and agency |
|
| ||
3:20 pm – 3:45 pm | Conference Closing Ceremony and invitation to ISSDP 2018: Vancouver, Canada | |||